Looking into the future with bioresorbable vascular scaffolds

References

• Konig A, Schiele TM, Rieber J et al. Influence of stent design and deployment technique on neointima formation and vascular remodeling. Z. Kardiol. 91(Suppl. 3), 98–102 (2002).
   PubMedGoogle Scholar
• Nakazawa G, Otsuka F, Nakano M et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. JACC 57, 1314–1322 (2011).
   Google Scholar
• Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109, 701–705 (2004).
   PubMed Web of Science ®Google Scholar
• Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 89, 651–656 (2003).
   PubMed Web of Science ®Google Scholar
• Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369, 1869–1875 (2007).
   PubMed Web of Science ®Google Scholar
• Haude M. Progress with drug-eluting magnesium resorbing stents (BIOTRONIK dreams program): DREAMS 2-year results. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Waksman R. Lessons learned from preclinical studies of magnesium scaffolds (Biotronik’s DREAMS program). Presented at: PCR focus group on bioresorbable vascular scaffolds. Rotterdam, NL, 8–9 March 2012.
   Google Scholar
• Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de novo coronary artery lesions (ABSORB): a prospective open label trial. Lancet 371, 899–907 (2008).
   PubMed Web of Science ®Google Scholar
• Tanimoto S, Bruining N, van Domburg RT et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J. Am. Coll. Cardiol. 52, 1616–1620 (2008).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58(15), 1578–88 (2011).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373, 897–910 (2009).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Onuma Y, on behalf of the ABSORB A & B investigators. ABSORB Cohort B: 6 m, 12 m, 18 m and 24 m follow-up. Presented at: PCR Focus Group on Bioresorbable Vascular Scaffolds. Rotterdam, NL, 8–9 March 2012.
   Google Scholar
• Diletti R, Farooq V, Girasis C et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort Btrial. Heart 99, 98–105, (2013)
   PubMed Web of Science ®Google Scholar
• Van Geuns R. BVS expand: first result of wide clinical applications of Bioresorbable Vascular Scaffold. Presented at: EuroPCR. Paris, FRA, 21–24 May 2013.
   Google Scholar
• Dudek D, Rzeszutko A, Lekston A et al. Bioresorbable Vascular Scaffolds (BVS) in patients with acute coronary syndrome. The muticenter registry in Poland: POLAR ACS. Presented at: EuroPCR. Paris, FRA, 21–24 May 2013.
   Google Scholar
• Widimsky P. Bioresorbable vascular scaffolds in acute STEMI: Prague-19 study. Presented at: EuroPCR. Paris, FRA, 21–24 May 2013.
   Google Scholar
• Serruys PW. An interim report on the 12-month clinical outcomes from the first 450 patients registered. Presented at: EuroPCR. Paris, FRA, 21–24 May 2013.
   Google Scholar
• Verheye S. DeSolve first in-man study preliminary results. Presented at: PCR Focus Group on Bioresorbable Vascular Scaffolds. Rotterdam, NL, 8–9 March 2012.
   Google Scholar
• Verheye S, on behalf of the DESolve investigators. First-in-Man results with a Myolimus-Eluting bioresorbable PLLA-based vascular scaffold (Elixir DESolve). Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Jabara R. Poly-anhydride based on salicylic acid and adipic acid anhydride. Presented at: EuroPCR. Barcelona, SPN, 19–22 May 2009.
   Google Scholar
• Jabara R. Bio-mechanical properties and ABC of bioresorption of adipic acid. Presented at: PCR Focus Group on Bioresorbable Vascular Scaffolds. Rotterdam, NL, 8–9 March 2012.
   Google Scholar
• Grube E. Bioabsorbable stent. The Boston scientific and REVA technology. Presented at: EuroPCR. Barcelona, SPN, 19–22 May 2009.
   Google Scholar
• Costa R. REVA ReZolve clinical program update. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA, 22–26 October 2012.
   Google Scholar
• Cottone RJ, Thatcher GL, Parker SP et al. OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings. EuroIntervention 5(Suppl. F), F65–71 (2009).
   PubMedGoogle Scholar
• Shen L, Wang Q, Wu Y, Xie J, Ge J. Short-term effects of sirolimus eluting fully bioabsorbable polymeric coronary stents in a porcine model. Presented at: Transcatheter Cardiovascular Therapeutics (TCT) conference. San Francisco, CA, 7–11 November 2011.
   Google Scholar
• Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102, 399–404 (2000).
   PubMed Web of Science ®Google Scholar
• Nishio S, Kosuga K, Igaki K et al. Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai Stents. Circulation 125, 2343–2353 (2012).
   PubMed Web of Science ®Google Scholar
• Lafont A. ART bioresorbable stent. Arterial remodeling in preclinical models. Presented at: PCR Focus Group On Bioresorbable Vascular Scaffolds. Rotterdam, NL, 8–9 March 2012.
   Google Scholar
• Gomez-Lara J, Garcia-Garcia HM, Onuma Y et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc. Interv. 3, 1190–1198 (2010).
   PubMed Web of Science ®Google Scholar
• Palmerini T, Sangiorgi D, Marzocchi A et al. Ostial and midshaft lesions vs. bifurcation lesions in 1111 patients with unprotected left main coronary artery stenosis treated with drug-eluting stents: results of the survey from the Italian Society of Invasive Cardiology. Eur. Heart J. 30, 2087–2094 (2009).
   PubMed Web of Science ®Google Scholar
• Ozaki Y, Okumura M, Ismail TF et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur. Heart J. 31, 1470–1476 (2010).
   PubMed Web of Science ®Google Scholar